Hexarelin is a GHRP, or growth hormone-releasing peptide, and is a synthetic hexapeptide. Hexarelin goes by several other names: EP-23905, MF-6003, and Examorelin. Hexarelin comprises the following amino acids: His, D-2-methyl-Trp, Ala-Trp, D-Phe-Lys, and NH2. There is no obvious sequence resemblance between ghrelin and this hexapeptide, which was synthesized from GHRP-6 (growth hormone-releasing peptide 6). It hasn't been shown, but some researchers hypothesize it may have agonistic potential at the ghrelin receptor and might thus imitate ghrelin's effects.
Several investigations on Hexarelin have suggested its strong selectivity for the ghrelin receptor, also known as GHSR1a (growth hormone secretagogue receptor 1a). Researchers have labeled it a growth hormone secretagogue due to its apparent potency in increasing growth hormone secretion. Differentiating it from other chemicals in its class is its specific activation of the GHSR1a. In addition, Hexarelin is a one-of-a-kind peptide that seems unaffected by digestive enzymes. Hexarelin's unique interactions with growth hormone secretagogue receptors, as well as its precise methods of action, are still the focus of active investigation.
Hexarelin Peptide, the Brain and Spinal Cord
Hexarelin is a peptide molecule that seems to interact with GHSR1a in the brain, perhaps setting off a chain reaction of intracellular signaling events that regulate several physiological processes. The high affinity and specificity of the binding site of GHSR1a receptors to Hexarelin is postulated to be responsible for this interaction.
Hexarelin may initiate intracellular signaling pathways after binding to GHSR1a receptors, as suggested by published research. Phospholipase C (PLC) activation is a biochemical byproduct of these pathways, which is thought to include the activation of G-proteins such as Gq/11. Phosphatidylinositol 4,5-bisphosphate (PIP2) is hydrolyzed by phosphatidylinositol kinase (PLK) to produce inositol triphosphate (IP3) and diacylglycerol (DAG). Calcium in the cytosol may rise if the release of IP3 triggers the release of intracellular calcium reserves. Calcium influx may control cellular functions such as neurotransmitter release, gene expression, and intracellular signaling cascades. Protein kinase C (PKC) may also be activated by DAG, with the resulting phosphorylation of target proteins possibly controlling cellular processes.
Potential activation of GHSR1a receptors by Hexarelin may lead to the release of particular hormonal compounds from the pituitary gland. The growth hormone (hGH), prolactin, adrenocorticotropic hormone (ACTH), and cortisol are all examples of such molecules. Furthermore, research suggests that the interaction between Hexarelin and GHSR1a receptors in the hippocampus may potentially alter neuronal function and communication. Whether or not it modulates synaptic plasticity, neurotransmitter release, or mechanisms involved in memory consolidation and cognitive functions is unclear, although it is thought to be important.
One research even looked at Hexarelin's possible protective impact on the brain, namely the hippocampus. The research used a carotid artery ligation and hypoxia exposure rat model of neonatal hypoxia-ischemia. After analyzing the results, the researchers speculated that "damage appeared reduced by 39% in the treatment group, compared with the vehicle group, and injury was considerably reduced in the cerebral cortex, hippocampus, and thalamus, but not in the striatum." Caspase-3 activity, an enzyme involved in cell death, was also reportedly reduced. In contrast, phosphorylation of Akt and glycogen synthase kinase-3beta were reported to have increased, both associated with decreased brain damage. Glycogen synthase kinase-3beta activity was suggested to be modulated by Akt activation, suggesting that Akt signaling may play a role in preventing caspase-dependent cell death and, therefore, cell death.
Hexarelin Peptide and GHSR1a Receptors
Hexarelin's possible interactions with pituitary ghrelin receptors and hypothalamic ghrelin receptors are intricate. It's also possible that other hormones may alter these connections. Some androgens, for instance, may be able to upregulate ghrelin receptors, which would improve their responsiveness to Hexarelin. Although the specific mechanisms of this relationship remain unclear, it is speculated that androgens may alter the expression or sensitivity of ghrelin receptors at the cellular level. Androgens may increase the expression or sensitivity of ghrelin receptors via modifying gene expression or intracellular signaling pathways. Hexarelin's activity and the apparent release of growth hormone may be enhanced if it has a higher binding affinity to these upregulated receptors, as has been hypothesized if this modulation occurs.
Conclusion
Finally, it seems that Hexarelin may interact with the ghrelin receptor (GHSR1a) in the brain. The fact that it may be resistant to breakdown by digestive enzymes further sets it apart from similar substances. Research suggests it may affect intracellular signaling pathways and increase growth hormone release from pituitary cells. Furthermore, it seems to function in synaptic plasticity, memory consolidation, and cognitive processes, and it may influence the release of particular hormone chemicals. It has been hypothesized the function of Hexarelin may be affected by its interactions with other hormones, such as androgens and growth hormone-releasing hormone (GHRH).
Licensed professionals interested in purchasing Hexarelin peptides for their studies may
click here to navigate to the Core Peptides website.
References
[i] Khatib, N., Gaidhane, S., Gaidhane, A. M., Khatib, M., Simkhada, P., Gode, D., & Zahiruddin, Q. S. (2014). Ghrelin: ghrelin as a regulatory Peptide in growth hormone secretion. Journal of clinical and diagnostic research : JCDR, 8(8), MC13–MC17.
https://doi.org/10.7860/JCDR/2014/9863.4767
[ii] Yin, Y., Li, Y., & Zhang, W. (2014). The growth hormone secretagogue receptor: its intracellular signaling and regulation. International journal of molecular sciences, 15(3), 4837–4855.
https://doi.org/10.3390/ijms15034837
[iii] Frieboes, R. M., Antonijevic, I. A., Held, K., Murck, H., Pollmächer, T., Uhr, M., & Steiger, A. (2004). Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology, 29(7), 851–860.
https://doi.org/10.1016/S0306-4530(03)00152-5
[iv] Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., Lenaerts, V., Wüthrich, P., & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans. A dose-response study. European journal of clinical pharmacology, 46(5), 421–425.
https://doi.org/10.1007/BF00191904
[v] Brywe, K. G., Leverin, A. L., Gustavsson, M., Mallard, C., Granata, R., Destefanis, S., Volante, M., Hagberg, H., Ghigo, E., & Isgaard, J. (2005). Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation. Endocrinology, 146(11), 4665–4672.
https://doi.org/10.1210/en.2005-0389
